🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "huge turning point" in the battle against drug-resistant strains of the infection, according to researchers.

A Global Health Concern

Cases of gonorrhoea are on the rise worldwide, with data suggesting over 82 million new cases each year. Especially elevated rates are reported in the African continent and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an important and timely step in the reality of rising global incidence, escalating drug resistance and the extremely scarce available drugs currently available.”

Medical experts are deeply concerned about the rise in treatment-resistant strains. The WHO has designated it as a "high-priority threat". Ongoing monitoring revealed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Receive Approval

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the American regulatory agency in mid-December for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Scientists anticipate that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, also received approval in concurrent days. This treatment, which is additionally indicated for UTIs, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The charitable organization GARDP worked alongside the pharmaceutical company Innoviva to develop it.

“This authorization marks a huge turning point in the treatment of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Research Study Results and Worldwide Availability

According to results published in a prominent scientific publication, zoliflodacin eradicated the vast majority of cases of the STI. This puts it on an comparable level with the existing first-line therapy, which uses a dual-drug approach. The trial enrolled nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, the non-profit has the ability to make available and distribute the drug in many low-income and middle-income countries.

Clinicians directly involved have voiced positive views. Having a single-dose, oral treatment such as this is seen as a "game-changer" for gonorrhoea control. This is considered crucial to alleviate the strain of the infection for people and to stop the proliferation of extremely resistant gonorrhoea worldwide.